INTRODUCTION
The two forms of solids are the crystalline form and the amorphous form. Solid materials are usually processed in their crystalline form, but application of the amorphous form is increasing. Glassy materials are used in many industrial fields glassy materials are used such as the plastics industry, the textile industry, the food industry, and for the production of semiconductors, ceramics and optical glasses, and naturally in the pharmaceutical industry.
In pharmaceutical formulations, most drug materials are processed in their crystalline form. This is a thermodynamically stable state that exhibits both short-range and long-range order. Unlike a crystalline solid, an amorphous solid has no long-range order of molecular packing, so the molecules are conformationally flexible. The application of an active pharmaceutical ingredient (API) in amorphous form is increasingly common in the development of pharmaceutical solid formulations, with all its risks and benefits.
What are the most important advantages of the application of the amorphous drugs?
Amorphous forms of APIs have many useful properties. Among the most important ones are a higher dissolution rate and a sometimes higher water solubility relative to that of the crystalline form as there is no lattice energy, which is a thermodynamic barrier to dissolution.
It must be mentioned that there are disadvantages to the use of this form. Amorphous solids generally have lower stability than the corresponding crystals because of the higher energy level. Crystallization inhibitors therefore have to be used in most cases in amorphous pharmaceutical technological formulations. A wide range of auxiliary agents are available to stabilize this form and to prepare a suitable glassy dosage form.
The pharmaceutical industry is highly interested in amorphous formulations because amorphization techniques are very innovative, thanks to the advances in the analytical methods. The detection of amorphous forms is currently a widely investigated field of pharmaceutical technology, as concern both deliberate amorphization and when an unwanted glassy form appears spontaneously during formulation or storage.
The most important review articles connected with amorphous materials in pharmaceutical technology, discussed preparation methods, characterization techniques and possibilities for the stabilization of glassy drugs. From a Hungarian aspect, our team first reported the advantages of amorphization in 2003 and used different methods in the industrial research and development work.
AIMS
The primary aim of this study was to establish the literature background of pharmaceutical amorphization. We wanted to know what methods are available to produce this special solid form, and how amorphous materials can be investigated and characterized with different analytical techniques.
The secondary aim was to investigate clopidogrel hydrogensulfate (CLP) as model drug from the aspect of pharmaceutical amorphization. The steps of this work were as follows:
-Characterization of the glassy property of CLP: determination of the investigation methods that can be used to classify CLP according to its glass formability (a poor or a good glass-former).
-Choice of a preparation method which results in pure amorphous CLP without use of an auxiliary agent.
-Investigation of the stability of pure amorphous CLP because of its tendency to undergo recrystallization during storage.
-Identification of a suitable recrystallization inhibitor and determination of its amount which can stabilize the amorphous form of CLP.
-Use of the amorphized product in a scaling-up process.
-Development of tablets as final dosage form that is appropriately stable as concern the recrystallization of CLP.
-Devising a protocol of amorphization in general, as a practical consideration.
It should be mentioned that the experimental part of this thesis was carried out in [2002] [2003] [2004] . In that period, the pharmaceutical industry was greatly in the amorphization of APIs. The amorphous form remains important nowadays but the approach has changed appreciably. Deliberate amorphization is still of great interest industrially, but in the scientific field, a new issue has arisen and has been subject to considerable development. This is when an amorphous form arises spontaneously during the pharmaceutical formulation or during storage. This can give rise to different properties which may cause problems in the processing technology or in the application of drugs.
MATERIALS AND METHODS

Materials
In this study, the crystalline API which was subjected to amorphization was CLP 
Methods
Preparation of pure amorphous CLP
Amorphous samples were made with the use of ethanol 96% v/v or methanol. 1.00 g CLP was dissolved in 10.00 g ethanol or 4.00 g methanol with the aid of a magnetic stirrer (Velp ® Scientifica, Europe) for 5 minutes at room temperature. The solvent was evaporated by two methods: with blown room temperature air or under vacuum (Binder, Germany).
1.00 g CLP was treated with 20.00 g acetone with magnetic mixing for 15 minutes at room temperature and the solvent was then evaporated off in vacuum (Binder, Germany). After drying, samples were pulverized in a porcelain mortar with a pestle. In the following steps, we used the sample which was prepared with ethanol and dried with room temperature air as amorphous reference sample. 
Selection of a crystallization inhibitor
Tablet-making
A larger amount of stabilized product was prepared with the production method employed for Sample 2. This product was the internal phase of the tablets. The mass of a tablet was 400 mg, containing 100 mg of CLP (Table II GmbH, Germany). Investigations were made with fresh and with stored tablets.
Investigation of stability of products
As recommended by international guidelines (ICH Q1A), we stored samples under two different conditions. Long-term testing was performed at 25±2 ºC with 60±5% RH, and accelerated testing at 40±2 ºC with 75±5% RH. Under both conditions, samples were stored in open and in closed containers; the duration of storage was 4 weeks.
RESULTS
Measurement of T g
T g is one of the most important parameters for amorphous materials. 
Confirmation of amorphous form
Prepared samples were measured primarily by DSC. With this method, characterization of the amorphous form is possible quickly. The starting material and 5 prepared samples were tested at first by DSC. The crystalline CLP melted 177.4 ºC (450.6 K).
The sample which was treated with acetone remained in the crystalline phase. The samples prepared in ethanol or methanol was transformed to the amorphous form both on drying through blowing with room-temperature air and under vacuum. The characteristic melting point disappeared completely from the DSC curves, which were virtually straight lines without any enthalpy changes; no T g could be detected. Samples were also tested by XRPD measurement. Diffractograms are to be seen in Figure 2 ; for clarity, the diffractograms are displaced along the y axis. This investigation supported the DSC results throughout. Figure 2 shows that the products prepared with ethanol or methanol, independently of the drying procedure, were converted to the amorphous form, because the peaks disappeared from the diffractograms, and the spectra became smooth. The sample treated with acetone remained in the crystalline phase, and the diffractogram of this preparation was the same as that of the crystalline starting material. To confirm that no degradation had occurred in the prepared samples, FT-IR analysis was performed. The amorphous and crystalline materials furnished the same spectra. Samples prepared with ethanol or methanol transformed to the amorphous form. The objective of ICH Q3C guideline is to recommend acceptable amounts for residual solvents in pharmaceuticals for the safety of the patient. ICH Q3C classifies ethanol into the less dangerous Class 3, while methanol is classified into the more dangerous Class 2.
Accordingly, we recomended the application of ethanol for the amorphization of CLP. 
Preliminary stability testing
In the case of amorphous materials, stability problems can occur because of the higher energy level. The possibility of recrystallization is very realistic. The amorphous CLP was subjected to preliminary stability testing. A sample prepared with ethanol was stored in a closed glass container at 23±2 ºC and 55±5 RH. It was observed that crystal growth started after 30 days (Figure 3) . The crystallinity of the sample increased for approximately 76 days and the crystal growth then stopped. sample stored for 96 days; G: sample stored for 109 days.
Selection of a crystallization inhibitor
Because of the fast recrystallization, the stability of CLP must be increased through the use of a crystallization inhibitor, which is the auxiliary agent in the tablet composition.
DSC curves of the reference CLP (crystalline and amorphous) and samples containing CLP can be seen in 
Amorphization in scaling-up processes
The next step was to stabilize amorphous CLP on the surface of the carrier. In this system, MCC was used as the carrier, which serves as a filler/binder in tablet making. In 
Preparation and investigation of tablets
The amorphization procedure applied for Sample 2 was used to make 1000 tablets.
Both fresh and stored tablets were investigated. In the thermoanalytical study, a physical mixture of the tablet components was also investigated because of the presence of the crystalline phase of CLP. The slight enthalpy changes detected in the curve indicate that this sample may contain a little crystalline phase. This sample was stored at 40 ºC and 75% RH in an open container for 4 weeks. Curves of other samples do not reveal any crystalline phase in the system. The XRPD investigations resulted in constant data. The fingerprint of CLP did not appear in the diffractogram. A feature of importance for tablet making was that the surface area of the amorphous product decreased, which was another stabilizing step in the formulation. We measured physical parameters of the fresh and stored tablets. These results are in harmony with the fact that amorphous materials are hygroscopic. In these changes, the presence of Polyplasdone XL 10, as superdisintegrant, also plays an important part.
PRACTICAL ASPECTS
The amorphization of CLP as a model API was studied, tablets containing amorphous CLP were produced, and the stability of the product was tested. On the basis of our study, the following approaches can be suggested for the preparation of different solid dosage forms with amorphized API. There are two different methods for the preparation of amorphous products. Figure 6 outlines the general differences between these two procedures. The second way can be defined as 'in-process' amorphization, because the classical technological formulation process is combined with amorphization of the API. -In the first step, a suitable solvent for the API should be selected. In this step, it is very important that the crystalline API should dissolve completely: any crystals remaining in the system can function as seeds and crystallization can start during evaporation of the solvent.
amount of this auxiliary agent required to maintain the API in amorphous form should be determined. In this step, several crystallization inhibitors should be screened and, if possible, the type of interaction between the API and the auxiliary agent should be investigated.
-In the third step, the amorphization process must be scaled up.
-In the fourth step, the amorphized API should be stabilized on the surface of a carrier. This is an important step in this protocol, because the API, the crystallization inhibitor and the carrier act together in this system to result in stable amorphous API during the technological process.
-In the fifth step, the external phase of the tablets should be mixed with the amorphized product. The mixing must be performed very carefully, because mechanical force can induce recrystallization.
-In the sixth step, the tablets should be pressed. Compression can be a further stabilizing step, fixing the amorphous form because of the smaller surface.
FIGURE 7:
Protocol of 'in-process' amorphization.
